Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Catalyst Pharmaceuticals CPRX: This commercial-stage biopharmaceutical company which is focused on the development and commercialization...
These two healthcare stocks may be deeply undervalued.
All three have exciting programs on the way.
These companies are still in the early innings of their growth potential.
With multiple drugs on the market and revenue ramping up, the sky's the limit.
The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be.
These diamonds in the rough won't stay down.
When evaluating investments, it helps to keep quarterly performance in context.